CN115768895A - 用于治疗冠状病毒科感染的适体 - Google Patents

用于治疗冠状病毒科感染的适体 Download PDF

Info

Publication number
CN115768895A
CN115768895A CN202180041090.7A CN202180041090A CN115768895A CN 115768895 A CN115768895 A CN 115768895A CN 202180041090 A CN202180041090 A CN 202180041090A CN 115768895 A CN115768895 A CN 115768895A
Authority
CN
China
Prior art keywords
aptamer
receptor
seq
cov
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041090.7A
Other languages
English (en)
Chinese (zh)
Inventor
安妮凯萨琳·哈伯兰
J·穆勒
格尔德·瓦卢卡特
P·戈特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Cures Holding AG
Original Assignee
Berlin Cures Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Cures Holding AG filed Critical Berlin Cures Holding AG
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Publication of CN115768895A publication Critical patent/CN115768895A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202180041090.7A 2020-04-09 2021-04-09 用于治疗冠状病毒科感染的适体 Pending CN115768895A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20168929.6 2020-04-09
EP20176023.8 2020-05-22
EP20176023 2020-05-22
EP20180781 2020-06-18
EP20180781.5 2020-06-18
EP20204036 2020-10-27
EP20204036.6 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (1)

Publication Number Publication Date
CN115768895A true CN115768895A (zh) 2023-03-07

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041090.7A Pending CN115768895A (zh) 2020-04-09 2021-04-09 用于治疗冠状病毒科感染的适体

Country Status (11)

Country Link
US (1) US12606828B2 (enExample)
EP (1) EP4133083A1 (enExample)
JP (1) JP2023521361A (enExample)
KR (1) KR20220166337A (enExample)
CN (1) CN115768895A (enExample)
AU (1) AU2021252151A1 (enExample)
BR (1) BR112022020439A2 (enExample)
CA (1) CA3175067A1 (enExample)
IL (1) IL297155A (enExample)
MX (1) MX2022012618A (enExample)
ZA (1) ZA202212179B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3007984T3 (en) * 2021-04-09 2025-03-21 Berlin Cures GmbH Aptamers for use in the treatment of coronaviridae infections
KR102937192B1 (ko) * 2023-01-25 2026-03-17 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608456A (zh) * 2011-03-07 2014-02-26 柏林夏瑞蒂医科大学 适体在自体免疫疾病的疗法和/或诊断中的用途
CN109983129A (zh) * 2016-11-23 2019-07-05 柏林制药股份有限公司 用于抑制和/或压制tlr9激活的适体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508473A (ja) * 2005-08-26 2009-03-05 アーケミツクス・コーポレイシヨン 高親和性でトロンビンに結合するアプタマー

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103608456A (zh) * 2011-03-07 2014-02-26 柏林夏瑞蒂医科大学 适体在自体免疫疾病的疗法和/或诊断中的用途
CN109983129A (zh) * 2016-11-23 2019-07-05 柏林制药股份有限公司 用于抑制和/或压制tlr9激活的适体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KA TO SHUM等: "Differential Inhibitory Activities and Stabilisation of DNA Aptamers against the SARS Coronavirus Helicase", CHEMBIOCHEM, vol. 9, 21 November 2008 (2008-11-21), pages 3037 *
WANBO TAI等: "Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 17, 19 March 2020 (2020-03-19), pages 613 *
YANLING SONG等: "Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV‑2 Spike Glycoprotein", ANAL. CHEM., vol. 92, 18 June 2020 (2020-06-18), pages 9895 *

Also Published As

Publication number Publication date
US12606828B2 (en) 2026-04-21
BR112022020439A2 (pt) 2022-11-29
IL297155A (en) 2022-12-01
JP2023521361A (ja) 2023-05-24
AU2021252151A1 (en) 2022-12-08
CA3175067A1 (en) 2021-10-14
MX2022012618A (es) 2022-11-07
ZA202212179B (en) 2025-03-26
KR20220166337A (ko) 2022-12-16
EP4133083A1 (en) 2023-02-15
US20230140490A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
US20230331837A1 (en) Oligonucleotides for reduction of pd-l1 expression
JP7267689B2 (ja) 自己抗体関連疾患に対する使用のためのアプタマー
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
US12606828B2 (en) Aptamers for use in the treatment of Coronaviridae infections
WO2012050611A2 (en) Aptamers to glycoprotein vi
WO2021205012A1 (en) Aptamers for use in the treatment of coronaviridae infections
CN119947747A (zh) 流感病毒疫苗
JP2026021387A (ja) コロナウイルス科感染の治療において使用するためのアプタマー
EP4605008A1 (en) Alpha-v beta-6 integrin ligands for extrahepatic delivery
HK40104624B (en) Aptamers for use in the treatment of coronaviridae infections
HK40104624A (en) Aptamers for use in the treatment of coronaviridae infections
CN117642179A (zh) 流感病毒核酸脂质颗粒疫苗
KR101643947B1 (ko) gHA1 단백질에 특이적으로 결합하는 RNA 앱타머 및 그를 포함하는 약학 조성물
NZ785335A (en) Oligonucleotides for reduction of pd-l1 expression
HK1237371B (en) Aptamers for use against autoantibody-associated diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination